EC Clinical and Medical Case Reports

The zooanthropogenic virus SARS-CoV-2 was first identified in December 2019 as the causative agent of the dangerous infectious disease COVID-19. As we move away from the official dates of the pandemic in all countries of the world, new clinical data are accumulating on the numerous sufferings of patients who have suffered the acute stage of the infection. It is generally accepted that 20% of people may have residual long-term symptoms lasting up to 12 weeks, and 2.3% longer lasting, up to indefinitely [1].

1. Sudre CH., et al. “Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App”. medRxiv (2020).
2. Subramanian A., et al. “Symptoms and risk factors for long COVID in non-hospitalized adults”. Nature Medicine 8 (2022): 1706-1714.
3. Liang W., et al. “Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus”. Gut6 (2020): 1141-1143.
4. Thachill J., et al. “ISTH interim guidance on recognition and management of coagulopathing in COVID-19”. Journal of Thrombosis and Haemostasis 5 (2020): 1023-1026.
5. Methodological recommendations. “Features of the course of Long-COVID infection. Therapeutic and rehabilitation measures". Therapy 1 (2022): 1-147.
6. Algorithms for diagnosis and treatment. “Management of patients with long-COVID and post-Covid complications (including antiviral/immunomodulatory therapy”. Therapy4S (2023): 34-50.
7. Katyukhin VN. “Experience in the Treatment of Postcovid Inflammation in Adults”. EC Clinical and Medical Case Reports2 (2023): 29-30.